Germany · Delayed Price · Currency is EUR Medios AG Earnings Call Transcripts
Fiscal Year 2026
-
Revenue rose 8.9% to €527.6M, but EBITDA pre fell 7.9% to €21.2M due to margin pressure. Guidance for 2026 is maintained, with profitability improvements expected in H2, driven by operational excellence and cost optimization.
Fiscal Year 2025
-
Revenue grew 10.4% to EUR 2.1 billion and EBITDA pre rose 17.8% to EUR 93.1 million, driven by both organic and inorganic growth. 2026 guidance targets up to 2% revenue growth and higher margins, with continued focus on profitability, cash flow, and disciplined capital allocation.
-
Record revenue and EBITDA pre growth were achieved, driven by both organic and inorganic expansion, with strong cash flow and margin improvements. Guidance for 2025 is confirmed, with continued focus on advanced therapies and further international growth.
-
Revenue grew 9.3% to EUR 992 million and EBITDA pre rose 48.8% to EUR 46.3 million, with margin expansion across all segments. Guidance for 2025 is confirmed, targeting EUR 2 billion revenue and EUR 96 million EBITDA pre, while strategic initiatives and international expansion continue.
-
Q1 2025 saw strong revenue and EBITDA growth, driven by international business and Ceban integration, with improved margins and confirmed full-year guidance. Executive transitions and new incentive plans were announced, supporting future growth and operational focus.
Fiscal Year 2024
-
Record Q3 and strong nine-month results driven by Ceban integration and margin focus, with revenue up 4% and EBITDA pre up over 20%. Guidance for 2024 is confirmed, with continued expansion in Europe and advanced therapies planned.
-
Revenue grew 6% to EUR 907 million in H1 2024, with EBITDA pre up 7% and strong cash flow. The Ceban acquisition was completed and integrated, boosting international presence and margins. 2024 guidance is confirmed, with continued focus on specialty pharma and advanced therapies.